A Phase 3 Open-Label Randomized Multi-Center Study of DZD9008 versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutation

Brief description of study

This is a phase 3, open-label, randomized, multi-center study assessing the efficacy and safety of DZD9008 versus platinum-based doublet chemotherapy in participants with locally advanced or metastatic NSCLC with EGFR Exon20ins mutation, who are newly diagnosed or have not received prior systemic therapy in advanced stage.


Clinical Study Identifier: s22-01383
ClinicalTrials.gov Identifier: NCT05668988
Principal Investigator: Elaine Shum.
Other Investigators: Joshua K Sabari, Samantha VanMaanen, Elka R Travis, Salman Rafi Punekar, Jessica Wang, Nitish Mehta, Carol M Lee, Marissa Rybstein, Sally Lau, Gabrielle Fridman, Danny Perlaza, James Newman, David Mendoza, Melissa L Martinez, Jonathan B Kahn, Jeffrey G Schneider, Avital Benson, Natalia Cherkassky, Laura Palazzolo, Vamsidhar Velcheti.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.